Meanwhile, hemophilia A drug Altuviiio reached nearly a quarter of a billion euros in sales in the fourth quarter, with Sanofi crediting that growth to an increasing number of patients switching ...
Sobi’s Sanofi-partnered efanesoctocog alfa has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA ...
Hosted on MSN1mon
Sanofi Down 10% in 3 Months: How Should You Play the Stock?Sanofi’s new products like novel recombinant factor VIII therapy, Altuviiio, respiratory syncytial virus (RSV) antibody, Beyfortus (in partnership with AstraZeneca [AZN]), Pompe disease therapy ...
The Sanofi Global Health Unit plays an important ... And the second question, a very short one, given the current dynamics with ALTUVIIIO, is that one your next blockbuster and no later than ...
Sanofi’s sales rose 10% on a constant currency rate (“CER”) basis, while earnings per share declined 11%. Higher sales of Dupixent and contributions from new products like Altuviiio and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results